Targeted oncology
Adjuvant Systemic Therapies After Nephrectomy for Renal Cell Carcinoma: A Bayesian Network Meta-Analysis and Multi-Criteria Benefit-Risk Assessment
By Yajima S, Okumura G, Yoshida S and 6 others.
Abstract
Background
Adjuvant pembrolizumab has improved disease-free survival after nephrectomy for high-risk renal cell carcinoma, and pembrolizumab plus belzutifan has further expanded the treatment landscape.
Objective
We compared efficacy and treatment burden across adjuvant systemic therapies and examined the benefit-risk trade-off of the combination.